Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

Launched by INSTITUT PAOLI-CALMETTES · Aug 17, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called pancreatic radiofrequency ablation (RFA) for patients with a type of tumor known as a pancreatic neuroendocrine tumor (PNET). Specifically, it focuses on tumors that are less than 2 centimeters in size and do not produce hormones that cause symptoms. The goal is to see if RFA can safely reduce or manage these tumors, offering patients an alternative to ongoing monitoring, which can be stressful and expensive.

To participate in the trial, individuals must be between 18 and 80 years old, have a specific type of PNET diagnosed through a biopsy, and be in generally good health. Participants will undergo the RFA treatment and will be monitored closely to assess how well it works and any side effects. This trial is open to all genders and is currently recruiting participants, so if you or someone you know meets the criteria, it could be a valuable opportunity to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
• • Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\<3%,
• • Non-secretory lesion.
• • Homogeneous HEE contrast taking;
• • No positron emission tomography (PET) FDG binding to the pancreatic mass;
• • Lesion \<20mm on conventional imaging at 6 months monitoring;
• • Age 18 to 80 years inclusive;
• • Patient in good general condition, World Health Organization \[0-1\];
• • Signed consent to participate;
• • Affiliation to healthcare insurance system or beneficiary of this regimen.
• Exclusion Criteria:
• • Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;
• • A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.
• • Life expectancy \< 1 year;
• • Severe hemostasis disorders;
• • Pancreatic and/or biliary ductal dilation;
• • Lesion considered to be adjacent to the pancreatic duct and/or bile duct;
• • Node extension and/or metastatic disease;
• • Patient being managed for another malignant lesion which is progressive or under treatment.